http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
-
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals (ZNTL) Appoints Kimberly Freeman as Chief Strategy Officer
-
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
-
Zentalis Pharmaceuticals (ZNTL) Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
-
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
-
Zentalis Pharmaceuticals (ZNTL) Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy
-
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
-
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combination
-
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
-
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from
-
Zentalis Pharmaceuticals (ZNTL) Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR
-
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
-
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals (ZNTL) Appoints Iris Roth as COO
-
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
-
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals (ZNTL) Announces First ZN-c3 Clinical Development Collaboration with Pfizer (PFE)
-
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
-
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals (ZNTL) Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer
-
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer
-
Zentalis Pharmaceuticals (ZNTL) Appoints Carrie Brownstein as Chief Medical Officer
-
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer
-
Zentalis Pharmaceuticals (ZNTL) Appoints Jan Skvarka to its Board
-
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
-
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
-
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference
-
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zentalis Pharmaceuticals (ZNTL) Names Andrea Paul as General Counsel as Alexis Pinto Resigns
-
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
-
Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference
-
Zentalis Pharmaceuticals (ZNTL) Promotes Cofounder Cam Gallagher to President

